Vertex doubles down on diabetes – acquires firm and resumes stem cell study

With the acquisition of Viacyte, a biotech firm focused on stem cell therapies to cure type 1 diabetes, Vertex hopes to accelerate development of its own candidate, which is moving forward following an FDA clinical hold.
by andreas lønstrup, translated by daniel pedersen

US-based Vertex Pharmaceuticals, a biotech firm developing a stem cell-derived candidate for the treatment of type 1 diabetes, is set to acquire a privately owned firm focused on the same area, Viacyte, a company press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading